Is 2-deoxy-2-[(18)F]fluoro-D-glucose PET/CT acquisition from the upper thigh to the vertex of skull useful in oncological patients?

Is 2-deoxy-2-[(18)F]fluoro-D-glucose PET/CT acquisition from the upper thigh to the vertex of skull useful in oncological patients?

To assess whether performing routinely 2-deoxy-2-[(18)F]fluoro-D-glucose PET/CT ((18)FDG PET/CT) scan from the upper thigh to the vertex of skull is clinically relevant. 3502 (1634 female; mean-age 60+16) consecutive patients undergoing (18)FDG PET/CT were retrospectively analyzed. Patients were div...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Translational medicine @ UniSa 2015-01, Vol.11, p.34-38
Hauptverfasser: Salvatore, B, Caprio, M G, Fonti, R, D'Amico, D, Fraioli, F, Salvatore, M, Pace, L
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 38
container_issue
container_start_page 34
container_title Translational medicine @ UniSa
container_volume 11
creator Salvatore, B
Caprio, M G
Fonti, R
D'Amico, D
Fraioli, F
Salvatore, M
Pace, L
description To assess whether performing routinely 2-deoxy-2-[(18)F]fluoro-D-glucose PET/CT ((18)FDG PET/CT) scan from the upper thigh to the vertex of skull is clinically relevant. 3502 (1634 female; mean-age 60+16) consecutive patients undergoing (18)FDG PET/CT were retrospectively analyzed. Patients were divided in 10 groups according to primary malignancy. Chi-square analysis was used to assess differences among proportions. A p value < 0.05 was considered significant. (18)FDG PET/CT was positive in head district in 130/3502 (3,7%) patients. In all patients lesions were unknown before PET/CT examination. PET/CT showed 158 positive brain/head uptake in the 130 patients. The 158 lesions were localized in: brain (43/158; 27%), bone (52/158; 33%), lymph node (1/158; 0,6%), soft tissue (55/158; 35%) and other sites (7/158; 4,4%). According to each group, patients were positive in the head district in 1.0% for Gastrointestinal Cancer (7/690), 3.0 % for Genitourinary Cancer (3/101), 3.7 % for Haemathologic Cancer (59/1590), 2.7 % for Gynaecologic Cancer (3/112), 7.8% for Head-Neck-Thyroid and Parathyroid Cancer (26/331), 3.5% for Breast Cancer (7/200), 2.6% for Lung Cancer (7/271), 3.4% for Melanoma (2/59), 7.4% for Sarcoma (2/27), 11.6% for Unknown Primary Tumour (14/121). Our data show a relatively high incidence of brain/head lesion in patients with Unknown Primary Tumour.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4309653</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1655258880</sourcerecordid><originalsourceid>FETCH-LOGICAL-p196t-90d742e43643b9203ea3901f3d61147b4c2d5625e110647a33caf1634745d1733</originalsourceid><addsrcrecordid>eNpVkE9Lw0AQxYMottR-BdljPSxm_ya5KFJbLRT0UE8iYbvZpKvbbJrdLe3ZL27UKjqXebwZ3o-Zo6iPMclgltDk-I_uRUPnXuOuUs55Rk6jHmY8oYwm_eh95gCGhbK7PcTweYTSi-lLaYJtLbyFlQnSOgUeJ4vL8QIIuQnaaa9tDcrWroFfKRCaRrWd0tUKePtlbVXr1Q7YEri3YAwITpXBAF0DW0trbKWlMKARXqvau-uz6KQUxqnhoQ-ip-lkMb6H84e72fhmDhuUcQ-zuEgoVpRwSpYZjokSJItRSQqOEE2WVOKCccwUQjGniSBEihJxQrtTC5QQMoiuvnObsFyrQnbwVpi8afVatPvcCp3_n9R6lVd2m1MSZ5x9BowOAa3dBOV8vtZOKmNErWxwOeKMYZamadytnv9l_UJ-Pk8-AFSkgSU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1655258880</pqid></control><display><type>article</type><title>Is 2-deoxy-2-[(18)F]fluoro-D-glucose PET/CT acquisition from the upper thigh to the vertex of skull useful in oncological patients?</title><source>PubMed Central Open Access</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Salvatore, B ; Caprio, M G ; Fonti, R ; D'Amico, D ; Fraioli, F ; Salvatore, M ; Pace, L</creator><creatorcontrib>Salvatore, B ; Caprio, M G ; Fonti, R ; D'Amico, D ; Fraioli, F ; Salvatore, M ; Pace, L</creatorcontrib><description>To assess whether performing routinely 2-deoxy-2-[(18)F]fluoro-D-glucose PET/CT ((18)FDG PET/CT) scan from the upper thigh to the vertex of skull is clinically relevant. 3502 (1634 female; mean-age 60+16) consecutive patients undergoing (18)FDG PET/CT were retrospectively analyzed. Patients were divided in 10 groups according to primary malignancy. Chi-square analysis was used to assess differences among proportions. A p value &lt; 0.05 was considered significant. (18)FDG PET/CT was positive in head district in 130/3502 (3,7%) patients. In all patients lesions were unknown before PET/CT examination. PET/CT showed 158 positive brain/head uptake in the 130 patients. The 158 lesions were localized in: brain (43/158; 27%), bone (52/158; 33%), lymph node (1/158; 0,6%), soft tissue (55/158; 35%) and other sites (7/158; 4,4%). According to each group, patients were positive in the head district in 1.0% for Gastrointestinal Cancer (7/690), 3.0 % for Genitourinary Cancer (3/101), 3.7 % for Haemathologic Cancer (59/1590), 2.7 % for Gynaecologic Cancer (3/112), 7.8% for Head-Neck-Thyroid and Parathyroid Cancer (26/331), 3.5% for Breast Cancer (7/200), 2.6% for Lung Cancer (7/271), 3.4% for Melanoma (2/59), 7.4% for Sarcoma (2/27), 11.6% for Unknown Primary Tumour (14/121). Our data show a relatively high incidence of brain/head lesion in patients with Unknown Primary Tumour.</description><identifier>ISSN: 2239-9747</identifier><identifier>EISSN: 2239-9747</identifier><identifier>PMID: 25674547</identifier><language>eng</language><publisher>Italy: Universitài Salerno</publisher><ispartof>Translational medicine @ UniSa, 2015-01, Vol.11, p.34-38</ispartof><rights>2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309653/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309653/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25674547$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Salvatore, B</creatorcontrib><creatorcontrib>Caprio, M G</creatorcontrib><creatorcontrib>Fonti, R</creatorcontrib><creatorcontrib>D'Amico, D</creatorcontrib><creatorcontrib>Fraioli, F</creatorcontrib><creatorcontrib>Salvatore, M</creatorcontrib><creatorcontrib>Pace, L</creatorcontrib><title>Is 2-deoxy-2-[(18)F]fluoro-D-glucose PET/CT acquisition from the upper thigh to the vertex of skull useful in oncological patients?</title><title>Translational medicine @ UniSa</title><addtitle>Transl Med UniSa</addtitle><description>To assess whether performing routinely 2-deoxy-2-[(18)F]fluoro-D-glucose PET/CT ((18)FDG PET/CT) scan from the upper thigh to the vertex of skull is clinically relevant. 3502 (1634 female; mean-age 60+16) consecutive patients undergoing (18)FDG PET/CT were retrospectively analyzed. Patients were divided in 10 groups according to primary malignancy. Chi-square analysis was used to assess differences among proportions. A p value &lt; 0.05 was considered significant. (18)FDG PET/CT was positive in head district in 130/3502 (3,7%) patients. In all patients lesions were unknown before PET/CT examination. PET/CT showed 158 positive brain/head uptake in the 130 patients. The 158 lesions were localized in: brain (43/158; 27%), bone (52/158; 33%), lymph node (1/158; 0,6%), soft tissue (55/158; 35%) and other sites (7/158; 4,4%). According to each group, patients were positive in the head district in 1.0% for Gastrointestinal Cancer (7/690), 3.0 % for Genitourinary Cancer (3/101), 3.7 % for Haemathologic Cancer (59/1590), 2.7 % for Gynaecologic Cancer (3/112), 7.8% for Head-Neck-Thyroid and Parathyroid Cancer (26/331), 3.5% for Breast Cancer (7/200), 2.6% for Lung Cancer (7/271), 3.4% for Melanoma (2/59), 7.4% for Sarcoma (2/27), 11.6% for Unknown Primary Tumour (14/121). Our data show a relatively high incidence of brain/head lesion in patients with Unknown Primary Tumour.</description><issn>2239-9747</issn><issn>2239-9747</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNpVkE9Lw0AQxYMottR-BdljPSxm_ya5KFJbLRT0UE8iYbvZpKvbbJrdLe3ZL27UKjqXebwZ3o-Zo6iPMclgltDk-I_uRUPnXuOuUs55Rk6jHmY8oYwm_eh95gCGhbK7PcTweYTSi-lLaYJtLbyFlQnSOgUeJ4vL8QIIuQnaaa9tDcrWroFfKRCaRrWd0tUKePtlbVXr1Q7YEri3YAwITpXBAF0DW0trbKWlMKARXqvau-uz6KQUxqnhoQ-ip-lkMb6H84e72fhmDhuUcQ-zuEgoVpRwSpYZjokSJItRSQqOEE2WVOKCccwUQjGniSBEihJxQrtTC5QQMoiuvnObsFyrQnbwVpi8afVatPvcCp3_n9R6lVd2m1MSZ5x9BowOAa3dBOV8vtZOKmNErWxwOeKMYZamadytnv9l_UJ-Pk8-AFSkgSU</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Salvatore, B</creator><creator>Caprio, M G</creator><creator>Fonti, R</creator><creator>D'Amico, D</creator><creator>Fraioli, F</creator><creator>Salvatore, M</creator><creator>Pace, L</creator><general>Universitài Salerno</general><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150101</creationdate><title>Is 2-deoxy-2-[(18)F]fluoro-D-glucose PET/CT acquisition from the upper thigh to the vertex of skull useful in oncological patients?</title><author>Salvatore, B ; Caprio, M G ; Fonti, R ; D'Amico, D ; Fraioli, F ; Salvatore, M ; Pace, L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p196t-90d742e43643b9203ea3901f3d61147b4c2d5625e110647a33caf1634745d1733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Salvatore, B</creatorcontrib><creatorcontrib>Caprio, M G</creatorcontrib><creatorcontrib>Fonti, R</creatorcontrib><creatorcontrib>D'Amico, D</creatorcontrib><creatorcontrib>Fraioli, F</creatorcontrib><creatorcontrib>Salvatore, M</creatorcontrib><creatorcontrib>Pace, L</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Translational medicine @ UniSa</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Salvatore, B</au><au>Caprio, M G</au><au>Fonti, R</au><au>D'Amico, D</au><au>Fraioli, F</au><au>Salvatore, M</au><au>Pace, L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is 2-deoxy-2-[(18)F]fluoro-D-glucose PET/CT acquisition from the upper thigh to the vertex of skull useful in oncological patients?</atitle><jtitle>Translational medicine @ UniSa</jtitle><addtitle>Transl Med UniSa</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>11</volume><spage>34</spage><epage>38</epage><pages>34-38</pages><issn>2239-9747</issn><eissn>2239-9747</eissn><abstract>To assess whether performing routinely 2-deoxy-2-[(18)F]fluoro-D-glucose PET/CT ((18)FDG PET/CT) scan from the upper thigh to the vertex of skull is clinically relevant. 3502 (1634 female; mean-age 60+16) consecutive patients undergoing (18)FDG PET/CT were retrospectively analyzed. Patients were divided in 10 groups according to primary malignancy. Chi-square analysis was used to assess differences among proportions. A p value &lt; 0.05 was considered significant. (18)FDG PET/CT was positive in head district in 130/3502 (3,7%) patients. In all patients lesions were unknown before PET/CT examination. PET/CT showed 158 positive brain/head uptake in the 130 patients. The 158 lesions were localized in: brain (43/158; 27%), bone (52/158; 33%), lymph node (1/158; 0,6%), soft tissue (55/158; 35%) and other sites (7/158; 4,4%). According to each group, patients were positive in the head district in 1.0% for Gastrointestinal Cancer (7/690), 3.0 % for Genitourinary Cancer (3/101), 3.7 % for Haemathologic Cancer (59/1590), 2.7 % for Gynaecologic Cancer (3/112), 7.8% for Head-Neck-Thyroid and Parathyroid Cancer (26/331), 3.5% for Breast Cancer (7/200), 2.6% for Lung Cancer (7/271), 3.4% for Melanoma (2/59), 7.4% for Sarcoma (2/27), 11.6% for Unknown Primary Tumour (14/121). Our data show a relatively high incidence of brain/head lesion in patients with Unknown Primary Tumour.</abstract><cop>Italy</cop><pub>Universitài Salerno</pub><pmid>25674547</pmid><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2239-9747
ispartof Translational medicine @ UniSa, 2015-01, Vol.11, p.34-38
issn 2239-9747
2239-9747
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4309653
source PubMed Central Open Access; PubMed Central; EZB Electronic Journals Library
title Is 2-deoxy-2-[(18)F]fluoro-D-glucose PET/CT acquisition from the upper thigh to the vertex of skull useful in oncological patients?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T19%3A42%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%202-deoxy-2-%5B(18)F%5Dfluoro-D-glucose%20PET/CT%20acquisition%20from%20the%20upper%20thigh%20to%20the%20vertex%20of%20skull%20useful%20in%20oncological%20patients?&rft.jtitle=Translational%20medicine%20@%20UniSa&rft.au=Salvatore,%20B&rft.date=2015-01-01&rft.volume=11&rft.spage=34&rft.epage=38&rft.pages=34-38&rft.issn=2239-9747&rft.eissn=2239-9747&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1655258880%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1655258880&rft_id=info:pmid/25674547&rfr_iscdi=true